Ayelet Borgida

Ms. Ayelet Borgida

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2020 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
JZJun Zhong
Jun Zhong
AJAshley Jermusyk
Ashley Jermusyk
LWLang Wu
Lang Wu
JHJason W Hoskins
Jason W Hoskins
ICIrene Collins
Irene Collins
LALaufey T Amundadottir
Laufey T Amundadottir
Although 20 pancreatic cancer susceptibility loci have been identified through genome-wide association studies in individuals of European ancestry, much of its heritability remains unexplained and the genes responsible largely unknown. To discover novel pancreatic cancer risk loci and possible causal genes, we performed a pancreatic cancer transcriptome-wide association study in Europeans using three approaches: FUSION, MetaXcan, and Summary-MulTiXcan. We integrated genome-wide association studies summary statistics from 9040 pancreatic cancer cases and 12 496 controls, with gene expression prediction models built using transcriptome data from histologically normal pancreatic tissue samples (NCI Laboratory of Translational Genomics [n = 95] and Genotype-Tissue Expression v7 [n = 174] datasets) and data from 48 different tissues (Genotype-Tissue Expression v7, n = 74–421 samples). We identified 25 genes whose genetically predicted expression was statistically significantly associated with pancreatic cancer risk (false discovery rate < .05), including 14 candidate genes at 11 novel loci (1p36.12: CELA3B; 9q31.1: SMC2, SMC2-AS1; 10q23.31: RP11-80H5.9; 12q13.13: SMUG1; 14q32.33: BTBD6; 15q23: HEXA; 15q26.1: RCCD1; 17q12: PNMT, CDK12, PGAP3; 17q22: SUPT4H1; 18q11.22: RP11-888D10.3; and 19p13.11: PGPEP1) and 11 at six known risk loci (5p15.33: TERT, CLPTM1L, ZDHHC11B; 7p14.1: INHBA; 9q34.2: ABO; 13q12.2: PDX1; 13q22.1: KLF5; and 16q23.1: WDR59, CFDP1, BCAR1, TMEM170A). The association for 12 of these genes (CELA3B, SMC2, and PNMT at novel risk loci and TERT, CLPTM1L, INHBA, ABO, PDX1, KLF5, WDR59, CFDP1, and BCAR1 at known loci) remained statistically significant after Bonferroni correction. By integrating gene expression and genotype data, we identified novel pancreatic cancer risk loci and candidate functional genes that warrant further investigation.

31 January 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
FBFelix Emile Gastonguay Beaudry
Felix Emile Gastonguay Beaudry
ZLZhihao Li
Zhihao Li
ABAyelet Borgida
Ayelet Borgida
AZAnudari Zorigtbaatar
Anudari Zorigtbaatar
XWXin Wang
Xin Wang
RGRobert C. Grant
Robert C. Grant
Comprehensive molecular profiling can identify alterations in biliary tract cancer (BTC) potentially treatable with targeted therapies. However, the impact of whole-genome and transcriptome sequencing (WGTS) on therapeutic decision-making in a public healthcare system is unknown. Here, BTC patients prospectively received WGTS to inform clinical care at a large Canadian academic cancer center. We characterized the proportion of targetable alterations, the treatment recommendations generated by a molecular tumor board, targeted therapies received, patient outcomes, and the financing of these treatments. A total of 55 patients with BTC prospectively underwent WGTS to inform clinical care. Of those 55, 28 (51%, 95% CI 38–64%) harbored targetable alterations. Molecular tumor boards recommended consideration of targeted therapies for 43 (78% CI: 66–87%) of 55 cases. Among the 15 patients who progressed to second-line therapy and harbored targetable alterations, 8 received nine targeted therapies. No targeted therapies were funded through the public system, and most therapies were funded through compassionate access programs from companies. These results highlight the challenges and potential for inequities when implementing precision oncology in a publicly funded healthcare system.

18 November 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
XWXin Wang
Xin Wang
JHJaime Ivan Haro-Silerio
Jaime Ivan Haro-Silerio
FBFelix E.G. Beaudry
Felix E.G. Beaudry
ABAyelet Borgida
Ayelet Borgida
FAFarnoosh Abbas-Aghababazadeh
Farnoosh Abbas-Aghababazadeh
RGRobert C. Grant
Robert C. Grant
Purpose: Biliary tract cancer (BTC) is the leading cause of death in patients with primary sclerosing cholangitis (PSC). PSC-related BTC is poorly understood, and the risks and benefits of conventional and immunotherapy treatments are unknown. We aimed to characterize clinical outcomes and genomes of PSC-related BTCs. Experimental Design: This was a retrospective cohort study of patients with BTC with underlying PSC treated at MD Anderson Cancer Center (N = 46) and Princess Margaret Cancer Centre (N = 16), which were contrasted to patients with non–PSC-related BTC (N = 146). We compared outcomes between PSC and non-PSC, and PSC treated with and without immunotherapy. A combination of targeted sequencing (N = 139), whole-genome sequencing (WGS; N = 27), and WGS with paired RNA sequencing (N = 33) delineated the genomic and transcriptomic landscape of PSC-associated BTCs. Results: In PSC-related BTC, the addition of immunotherapy to chemotherapy was associated with improved first-line progression-free survival (PFS; N = 22 vs. 11; median PFS, 12.2 vs. 4.7 months; P = 0.01). Immune-related adverse events were rare (N = 2, 12.5%) and improved after treatment discontinuation. Classic actionable genomic alterations, including IDH1 mutations and FGFR2 fusions, were absent in PSC-related BTCs. PSC tumors had a 2.6-fold higher tumor mutational burden (P = 3.28e−05) compared with non-PSC tumors. Transcriptomic profiling revealed a subset of PSC tumors displaying RNA signatures of immunotherapy response. Conclusions: Immunotherapy in PSC-associated BTCs seemed safe, with a potential signal of effectiveness. Given the sample size and retrospective design, these results are hypothesis-generating. Together, these results demonstrate the unique biology underlying PSC-associated BTCs, highlighting the need for prospective trials and the development of specialized treatment strategies.

20 August 2025 in bioRxiv
Verified
Preprint
Open access
NSNoor Shakfa
Noor Shakfa
FNFerris Nowlan
Ferris Nowlan
SDSibyl Drissler
Sibyl Drissler
TTTiak Ju Tan
Tiak Ju Tan
ESElizabeth Sunnucks
Elizabeth Sunnucks
HJHartland W. Jackson
Hartland W. Jackson
Distinctively, pancreatic ductal adenocarcinoma (PDAC) consists of sparse tumour lesions intertwined with extensive desmoplastic stroma. The complexity of tumour-microenvironment interactions within this desmoplasia poses a challenge for accurate tumour profiling and patient stratification, and characterizes a profoundly chemoresistant tumour. Here we mapped the spatial relationships between tumour, stroma, and immune cell compartments delineating tumour and microenvironment types that expand the classical to basal spectrum of human PDAC. We used imaging mass cytometry to profile the in situ multi-cellular organization of 81 cell types in resected cases with paired whole genome sequencing. Cell types, functions, and pathway activation were distributed as highly reproducible environments in discrete locations throughout these tumours, which we deep-profiled using laser-capture mass spectrometry. We show that the connections between tumour phenotypes, vascularization, immune response, and stromal biophysical state are reinforced by genomic aberrations, altered by treatment, and associated with patient outcome. Predictive machine-learning models showed that spatial single cell data outperformed genomic or clinical features but integrated multi-omics models provide the best prediction of patient survival with compressed models requiring only 10 non-redundant robust molecular measures associated with the phenotypic spectrum of PDAC. Together, these findings define a phenotypic and molecular framework of PDAC that captures tumour-microenvironment co-dependencies and offers a refined basis for patient stratification and therapeutic targeting.

31 March 2023
Verified
Other
Open access
YWYifan Wang
Yifan Wang
JPJin Yong Patrick Park
Jin Yong Patrick Park
APAlain Pacis
Alain Pacis
RDRobert E. Denroche
Robert E. Denroche
GJGun Ho Jang
Gun Ho Jang
GZGeorge Zogopoulos
George Zogopoulos
Supplementary Table 3 shows the establishment of primary cell cultures from HRD PDAC xenografts

31 March 2023
Verified
Other
Open access
YWYifan Wang
Yifan Wang
JPJin Yong Patrick Park
Jin Yong Patrick Park
APAlain Pacis
Alain Pacis
RDRobert E. Denroche
Robert E. Denroche
GJGun Ho Jang
Gun Ho Jang
GZGeorge Zogopoulos
George Zogopoulos
Supplementary Figure 2 shows the results of a pilot monotherapy trial to evaluate regimen-related toxicity